Mark Sentenac and Simran Modi analyze the California Supreme Court's decision in the Gilead Tenofovir cases. The ruling marks a significant development in product liability law, rejecting a proposed duty requiring drug manufacturers to bring allegedly safer alternatives to market more quickly. The article explores the court's reasoning, the limits of the decision, and how advances in AI may shape future disputes over pharmaceutical R&D decisions.

Read More